Abstract
Background/Objective Cortical spreading depolarization (SD) is increasingly recognized as a major contributor to secondary brain injury. Monitoring SDs could be used to institute and guide SD-based therapeutics if noninvasive detection methods were available. Our primary objective is to use a high density array of electrodes to compare scalp direct current (DC)-shifts to SDs detected by gold standard electrocorticography (ECoG) to establish proof-of-concept validation that scalp DC-potentials can potentially provide noninvasive SD detection. Our secondary objective is to assess usability and artifact tolerance.
Methods An 83×58 mm thermoplastic elastomer array with 29 embedded 6-mm diameter Ag/AgCl 1-mcm spaced electrodes, the CerebroPatch™ Proof-of-Concept Prototype, was adhesively placed on the forehead with an intervening electrode gel interface to record DC-electroencephalography in normal volunteers and severe acute brain injury patients in the neuro-intensive care unit some with and some without invasive subdural ECoG electrodes. The scalp and ECoG voltages were collected by a Moberg® Advanced ICU Amplifier. Artifacts were visually identified and usability issues were recorded. SD was scored on ECoG using standard criteria of DC shift with associated suppression of high frequency activity with propagation across the electrode. A six parameter Gaussian plus quadratic baseline model was used to produce time-course ECoG and scalp electrode channel plots and heat-map movies of scalp voltages. The similarity of the noninvasive scalp and invasive ECoG DC-shift time-courses was compared via the Gaussian fit parameters and confirmed if the Coefficient-of-Determination exceeded 0.80.
Results Usability and artifact issues obscured most scalp Prototype device data except for 38 of the 140 ECoG-coded SDs over a period of 11 days in one sub-arachnoid hemorrhage patient. 26 of these DC-shifts were in readable, artifact free portions of scalp recordings and 24 had an acceptable, >0.80 Coefficient-of-Determination (0.98 [0.02], median [IQR]) between invasive ECoG and noninvasive Prototype device DC-shifts. These data suggest that these scalp DC-shifts (peak −457 ± 69 µV [mean ± StD], full-width-half maximum 70.9 ± 5.92 sec, area 18.7 ± 2.76 cm2) depicted in the heat-map movies represent noninvasively detected SDs.
Conclusions These results suggest that noninvasive SD detection is possible using scalp DC-potential signals with a high spatial resolution EEG array. Efforts to limit artifact and improve usability in DC-EEG detection are needed in order to improve the reliability of this approach and enable multi-modal monitoring for secondary brain injury.
Competing Interest Statement
Stephen C. Jones and Samuel J. Hund are founding partners and shareholders of CerebroScope. Benjamin R. Brown is a consultant to and shareholder of CerebroScope and Eric L. Singer is a shareholder of CerebroScope.
Funding Statement
This project was conducted for CerebroScope, a medical device company developing a scalp DC-EEG system for detecting SDs in sABI, concussion, and migraine. This work was partially supported by grants from the: US Public Health Service National Institutes of Health: NS30839, NS30839-14S1 and NS66292 to the SCJ while at the Allegheny-Singer Research Institute; and 5R43NS092181 and 3R43NS092181-02S1 to SCJ for CerebroScope.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of New Mexico Human Research Protections Office gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
